Physician profile
Natalia Yermakov
NPI 1801029301
$2,174.70
in general payments reported to CMS, 2019-2025
15 companies · $93.33 in 2025
The $93.33 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $426 · 2023: $412 · 2024: $636 · 2025: $93.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.87 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $343.34 | 2021-2023 | Belbuca |
| Biodelivery Sciences International, INC. | $142.59 | 2021 | |
| Galderma Laboratories, L.P. | $98.88 | 2021-2022 | |
| Averitas Pharma INC. | $83.36 | 2023 | Qutenza |
| Boston Scientific Corporation | $76.21 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.48 | 2021-2022 | |
| Nevro Corp. | $66.15 | 2021-2022 | |
| Vertos Medical, INC. | $53.86 | 2022 | |
| Lilly USA, LLC | $52.70 | 2022-2023 | Emgality |
| Stimwave Technologies Incorporated | $49.26 | 2021 | |
| Revance Therapeutics, INC. | $24.76 | 2025 | Daxxify |
| Amgen INC. | $20.17 | 2021 | |
| Allergan, INC. | $18.92 | 2021 | |
| Curonix LLC | $7.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Yermakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.